Lupin gains on FDA nod for generic oral contraceptive drug
Lupin received approval from the FDA to market a generic version of Warner Chilcott Company LLC's 'Ovcon 35' tablets, an oral contraceptive, in the American market.
Lupin is trading higher by 1.3% at Rs 865 on NSE after the pharmaceutical company said that it has received approval from the United States Food and Drug Administration (US FDA) to market a generic version of Warner Chilcott Company LLC's 'Ovcon 35' tablets, an oral contraceptive, in the American market.
The company has received final approval for its VyfemlaTM Tablets (Norethindrone and Ethinyl Estradiol Tablets USP, 0.4mg/0.035 mg) from the US FDA. Lupin's US subsidiary Lupin Pharmaceuticals Inc. shall commence marketing the product shortly, the company said in a regulatory filing.
According to IMS MAT March sales data, Warner Chilcott Company's Ovcon 35 tablets had annual US sales worth around $22.3 million.
The stock opened at Rs 855 and has seen a combined nearly 90,000 shares changing hands on the counter till 0945 hours on NSE and BSE.
The company has received final approval for its VyfemlaTM Tablets (Norethindrone and Ethinyl Estradiol Tablets USP, 0.4mg/0.035 mg) from the US FDA. Lupin's US subsidiary Lupin Pharmaceuticals Inc. shall commence marketing the product shortly, the company said in a regulatory filing.
According to IMS MAT March sales data, Warner Chilcott Company's Ovcon 35 tablets had annual US sales worth around $22.3 million.
The stock opened at Rs 855 and has seen a combined nearly 90,000 shares changing hands on the counter till 0945 hours on NSE and BSE.